ImmuCell Corp. (NASDAQ:ICCC) said the stock purchaseagreement with Cambridge Biotech Corp. became effective onTuesday.
Cambridge acquired a 15 percent stake in ImmuCell through astock purchase and was granted two options that could allowCambridge an additional interest in ImmuCell later.
ImmuCell anticipates it will be allowed a listing on theNASDAQ Small-Cap Market with the equity raised from thetransaction.
The companies intend to collaborate in the use of passiveimmunotherapy for the treatment of human disease and in thedevelopment of animal health products.
(c) 1997 American Health Consultants. All rights reserved.